DE60136084D1 - Antiangiogenische polypeptide und verfahren zur angiogenesehemmung - Google Patents

Antiangiogenische polypeptide und verfahren zur angiogenesehemmung

Info

Publication number
DE60136084D1
DE60136084D1 DE60136084T DE60136084T DE60136084D1 DE 60136084 D1 DE60136084 D1 DE 60136084D1 DE 60136084 T DE60136084 T DE 60136084T DE 60136084 T DE60136084 T DE 60136084T DE 60136084 D1 DE60136084 D1 DE 60136084D1
Authority
DE
Germany
Prior art keywords
angiogenesis inhibition
antiangiogenic polypeptides
antiangiogenic
polypeptides
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60136084T
Other languages
English (en)
Inventor
Jack Henkin
Donald J Davidson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Application granted granted Critical
Publication of DE60136084D1 publication Critical patent/DE60136084D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
DE60136084T 2000-09-29 2001-09-27 Antiangiogenische polypeptide und verfahren zur angiogenesehemmung Expired - Fee Related DE60136084D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67522600A 2000-09-29 2000-09-29
US94270401A 2001-08-31 2001-08-31
PCT/US2001/042423 WO2002026782A2 (en) 2000-09-29 2001-09-27 Antiangiogenic polypeptides and methods for inhibiting angiogenesis

Publications (1)

Publication Number Publication Date
DE60136084D1 true DE60136084D1 (de) 2008-11-20

Family

ID=27101293

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136084T Expired - Fee Related DE60136084D1 (de) 2000-09-29 2001-09-27 Antiangiogenische polypeptide und verfahren zur angiogenesehemmung

Country Status (13)

Country Link
EP (1) EP1320589B1 (de)
JP (2) JP2004526416A (de)
AR (1) AR030631A1 (de)
AT (1) ATE410507T1 (de)
AU (1) AU2002211837A1 (de)
BR (1) BR0110421A (de)
CA (1) CA2420672A1 (de)
DE (1) DE60136084D1 (de)
ES (1) ES2313987T3 (de)
MX (1) MXPA03002778A (de)
PE (1) PE20020376A1 (de)
UY (1) UY26929A1 (de)
WO (1) WO2002026782A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2502304C (en) 2002-10-08 2013-10-01 Genencor International, Inc. Phenolic binding peptides
AU2012203658B2 (en) * 2007-01-10 2014-05-08 Protgen Ltd. Complexes comprising angiostatin and its fragments, preparation preparing methods and uses thereof
CN101219219B (zh) 2007-01-10 2013-02-13 北京普罗吉生物科技发展有限公司 包含血管抑素或其片段的复合物、其制备方法及应用
FR2915102B1 (fr) * 2007-04-23 2014-05-16 Pf Medicament Utilisation d'un anticorps anti-cxcr4 pour le traitement du cancer
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
EP2486004B1 (de) 2009-10-09 2017-05-03 Zafgen, Inc. Sulfonverbindungen zur verwendung in der behandlung von adipositas
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
AU2011281037B2 (en) 2010-07-22 2014-11-27 Zafgen, Inc. Tricyclic compounds and methods of making and using same
WO2012064928A1 (en) 2010-11-10 2012-05-18 Zafgen Corporation Methods and compositions for treating thyroid hormone related disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
CN103402989B (zh) 2011-01-26 2016-04-06 扎夫根股份有限公司 四唑化合物及其制备和使用方法
CA2835195A1 (en) 2011-05-06 2012-11-15 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
EP2705035B1 (de) 2011-05-06 2016-12-14 Zafgen, Inc. Tricyclische pyrazolsulfonamidverbindungen sowie verfahren und herstellung zu ihrer herstellung
EP2705030B1 (de) 2011-05-06 2016-07-27 Zafgen, Inc. Teilweise gesättigten trizyklishen verbindungen, deren herstellung und verwendung
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
BR112014017673A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
EP2850079B1 (de) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol derivate,verfahren zu deren herstellung und deren verwendung
EA028367B1 (ru) 2012-11-05 2017-11-30 Зафджен, Инк. Способы лечения заболеваний печени
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
EP2925737B1 (de) 2012-11-05 2017-06-14 Zafgen, Inc. Tricyclische verbindungen zur verwendung bei der behandlung und/oder kontrolle von adipositas
KR20150126924A (ko) 2013-03-14 2015-11-13 자프겐 인크. 신장 질환 및 기타 장애의 치료 방법
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2204726A1 (en) * 1994-11-09 1996-12-27 Robin E. Offord Functionalized polymers for site-specific attachment
PL323256A1 (en) * 1995-04-26 1998-03-16 Childrens Medical Center Angiostatin fragments and angiostatin aggregate and method of using them
DK0910571T3 (da) * 1996-05-03 2005-10-31 Abbott Lab Hidtil ukendte antiangiogene peptider, polynucleotider, der koder for samme, samt fremgangsmåder til inhibering af angiogenese
WO1999045026A1 (en) * 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
ATE399567T1 (de) * 1998-04-28 2008-07-15 Serono Lab Peg konjugate von lhrh analogen
KR20000018933A (ko) * 1998-09-07 2000-04-06 김승수 내피세포 성장억제 활성을 가지는 사람 프로트롬빈 크링글단백질 및 이를 암호하는 유전자

Also Published As

Publication number Publication date
WO2002026782A2 (en) 2002-04-04
JP2004526416A (ja) 2004-09-02
MXPA03002778A (es) 2004-05-04
UY26929A1 (es) 2002-04-26
PE20020376A1 (es) 2002-05-13
ES2313987T3 (es) 2009-03-16
AU2002211837A1 (en) 2002-04-08
JP2008231107A (ja) 2008-10-02
BR0110421A (pt) 2005-08-30
AR030631A1 (es) 2003-08-27
WO2002026782A3 (en) 2003-01-16
CA2420672A1 (en) 2002-04-04
EP1320589A2 (de) 2003-06-25
EP1320589B1 (de) 2008-10-08
ATE410507T1 (de) 2008-10-15

Similar Documents

Publication Publication Date Title
DE60136084D1 (de) Antiangiogenische polypeptide und verfahren zur angiogenesehemmung
DE69927321D1 (de) Gerätesteuerungseinrichtung und Verfahren zur Bestimmung des Gerätes
DE60130836D1 (de) Architektur und Verfahren zur Kontextumschaltung
DE60103218D1 (de) Zugagangspunkt und Verfahren zur Verbindungssteuerung
DE60043034D1 (de) Verfahren und Zusammensetzung zur Entfernung von Photoresistschichten
DE60033068D1 (de) Verfahren und System zur Steuerung des Weiterreichens
DE60044921D1 (de) Programm und Verfahren zur Positionsbestimmung
DE60130779D1 (de) Verfahren und gerät zum kontrolieren des verteilens und der benutzung von digitalwerken
DE60042184D1 (de) Verfahren und Zusammensetzung zur Entschichtung von Photoresist
DE60205817D1 (de) Verfahren zur Erfassung und Beseitigung des Memory-Effektes
DE60017955D1 (de) Verfahren und zusammensetzungen zur peptidsynthese
DE10083668T1 (de) Knochenzementmischer und Verfahren
DE59908185D1 (de) Verfahren und Steuereinrichtung zur Minimierung von Unfallfolgen
DE60018907D1 (de) Verfahren und zusammensetzung zur zementierung von bohrlöchern
DE60025693D1 (de) Gerät und Verfahren zur Erkennung der Ursache einer Teilentladung
DE60107142D1 (de) Verfahren und Vorrichtung zur Detektierung von Schalterbetätigungen
DE50009293D1 (de) Verfahren und anordnung zur fern-zugangssteuerung
DE69619654D1 (de) Verfahren und gerät zur überspielungssteuerung
DE60018894D1 (de) Verfahren und System zur Beschichtung
DE60128788D1 (de) Zusammensetzung und verfahren zur bekämpfung von pflanzenschädlichen arthropoden
DE60127546D1 (de) Verfahren und magnetische vorrichtung zur bestimmung der orientierung
DE60009228D1 (de) Verfahren und Gerät zur arithmetischen Steurung
DE69923839D1 (de) Verfahren zur reindarstellung von terephthalsäure und isophthalsäure aus xylolgemischen
DE60033776D1 (de) Verfahren und Anordnung zur Reduzierung des Spitzen -Programmierstroms
DE60032808D1 (de) Verfahren und system zur optimalisierung des gebrauchs der funkverbindung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee